Andy is the Chief Scientific Officer (CSO) at o2h Discovery. He also leads scientific evaluations for investments and provides strategic scientific support across key portfolio projects for o2h Ventures. With over 25 years of experience as a Medicinal Chemist, Andy has worked with major pharmaceutical companies, including Sanofi-Aventis and AstraZeneca. He has contributed across all phases of drug discovery and has played a key role in advancing five candidates into clinical trials. Andy is also the author and inventor of over 55 publications and patents.